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Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer death
among men in Western countries. Current screening techniques are based on the measurement of serum prostate
specific antigen (PSA) levels and digital rectal examination. A decisive diagnosis of PCa is based on prostate
biopsies; however, this approach can lead to false-positive and false-negative results. Therefore, it is important to
discover new biomarkers for the diagnosis of PCa, preferably noninvasive ones. Metabolomics is an approach that
allows the analysis of the entire metabolic profile of a biological system. As neoplastic cells have a unique
metabolic phenotype related to cancer development and progression, the identification of dysfunctional metabolic
pathways using metabolomics can be used to discover cancer biomarkers and therapeutic targets. In this study,
we review several metabolomics studies performed in prostatic fluid, blood plasma/serum, urine, tissues and
immortalized cultured cell lines with the objective of discovering alterations in the metabolic phenotype of PCa and
thus discovering new biomarkers for the diagnosis of PCa. Encouraging results using metabolomics have been
reported for PCa, with sarcosine being one of the most promising biomarkers identified to date. However, the use
of sarcosine as a PCa biomarker in the clinic remains a controversial issue within the scientific community. Beyond
sarcosine, other metabolites are considered to be biomarkers for PCa, but they still need clinical validation.
Despite the lack of metabolomics biomarkers reaching clinical practice, metabolomics proved to be a powerful
tool in the discovery of new biomarkers for PCa detection.
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Systems biology applied to cancer research encompasses the “omics”
tools, including genomics, transcriptomics, proteomics, and metabo-
lomics, which complement each other and are capable of measuring
changes in several entities (genes, transcripts, proteins, or metabolites,
respectively) simultaneously, providing an overview of various
physiological or pathological conditions [1–3].
Metabolomics can provide an idea of the physiological status of a
biological system, and therefore, alterations in the “normal”
metabolome may be indicative of disease. These alterations in the
“normal” metabolome have the potential to deliver new diagnostic
markers for the detection and prognosis of diseases and to monitor the
response to therapeutic interventions [4]. Metabolomics also has the
potential to give new understanding of the phenotypic changesresultant from genetic alterations, environmental influence, and
toxicological influence [5].
The term metabolomics includes the assessment of all the
endogenous metabolites produced by the organism including small
molecule intermediates and end products of biochemical reactions in
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such as drugs, products from the body flora, and food. Instead of genes
and proteins that participate in these biological processes, the
metabolites produced are indicators of what is happening in the
metabolism of a cell in physiological or pathophysiological conditions.
Thus, metabolites can be altered in such diseases as cancer [1,6–9].
As neoplastic cells have a unique metabolic phenotype related to
cancer development and progression, the identification of dysfunc-
tional metabolic pathways through metabolomics can be used to
identify cancer biomarkers and discover therapeutic targets [5,6,10].
Prostate Cancer
Prostate cancer (PCa) is the second most diagnosed cancer in men
[11], principally affecting men over 50 years old [12], and is the fifth
leading cause of cancer-related deaths in men worldwide [11].
Statistically, in 25% of men worldwide with PCa that develop
metastatic disease [13], the bones are the principal targets of PCa
metastasis [14]. Given that PCa has a long latency period and is
potentially curable, it is essential to develop efficient and precocious
screening methods for its early detection and characterization [12].
The quantification of prostate serum antigen (PSA) and the digital
rectal examination are the most common screening techniques used
for PCa diagnosis. However, performing a prostate biopsy is
mandatory for a final diagnosis [12]. Serum PSA levels higher than
4.0 ng/ml are a sign of PCa [14], although PSA is not able to
differentiate patients with aggressive PCa from those with indolent
disease [15]. The value of PSA screening is also controversial because
of its limited sensitivity and specificity [1,16]. Recent studies
suggested that certain PCa patients may present with PSA levels
below 4.0 ng/ml [14]. This fact leads to false negatives, as no reliable
cutoff values exist to demonstrate the unequivocal presence of PCa
[16,17]. Furthermore, PSA levels may be affected by several other
factors, such as age, prostatitis, urinary tract infection, and benign
prostate hyperplasia, leading inevitably to false-positive results
[14,16,18,19].
The biopsy analysis can also provide false-negative results when the
tumor is small; when the cancer cells are distributed heterogeneously;
and in early PCa stage when, histologically, the tumor appears benign
[20–22]. Thus, samples obtained during the biopsy for histopatho-
logic analysis may not be representative of the cancer [23].
The lack of a consistent biomarker for PCa diagnosis and
monitoring highlights the need for novel, specific, sensitive, and
cost-effective biomarkers to implement the best treatment approach
in a precocious state of the disease [14].Altered Metabolism of PCa Cells
In 1920, Otto Warburg discovered that cancer cells, unlike
nonmalignant cells, preferentially produce ATP through the
glycolytic pathway (anaerobic pathway) instead of the Krebs cycle,
even in the presence of oxygen. This capability of cancer cells to
sustain high rates of glycolysis for ATP generation is known as the
Warburg effect [24–26].
Despite the relevance of the Warburg effect in cancer cells, the
Krebs cycle and oxidative phosphorylation also play an important role
in many types of cancer, including PCa. Recent evidence suggests that
increased citrate oxidation is an important metabolic characteristic in
PCa that supports the high cellular energy demand [27]. One of the
major functions of prostate cells is the production of citrate, PSA, and
polyamines, such as spermine, which are the major components ofprostatic fluid. Therefore, prostate cells have a distinct metabolic profile as
they produce specific compounds [1,16]. The production of citrate by
prostate cells is very high in comparison with other organs [28]. Unlike
other cells in the organism, prostate cell metabolism significantly favors
citrate synthesis over citrate utilization, which makes the prostate
peripheral zone epitheliumunique among human cells [29]. Usually, cells
degrade citrate in aerobic ATP production, with citrate being oxidized
during the Krebs cycle as part of the intermediary metabolism of glucose.
However, nonmalignant prostate cells accumulate and secrete citrate. The
oxidation of citrate is catalyzed by mitochondrial aconitase (m-aconitase).
In normal prostate cells, m-aconitase is inhibited by the high intracellular
concentrations of zinc, leading to citrate accumulation (Figure 1) [28,29].
Extensive metabolic alterations occur when prostate cells experience
neoplastic transformation. One of the most relevant alterations is citrate
oxidation, because cancer cells are unable to accumulate zinc, andwithout
elevated levels of zinc, m-aconitase is no longer inhibited and can catalyze
citrate oxidation [2,4,27,28,30]. This transformation of citrate accumu-
lation in healthy prostate cells to oxidized citrate in malignant prostate
cells results in more efficient energy production. This is probably an early
event in the progression tomalignancy and precedes the histopathological
identification of malignant cells [27,31,32].
For citrate synthesis, oxaloacetate and acetyl-coenzyme A (acetyl-
CoA) are essential, but whereas oxaloacetate is regenerated in the
Krebs cycle, acetyl-CoA is consumed. To ensure that cancer cells have
the needed energy for rapid proliferation, it is necessary to maintain
elevated rates of citrate oxidation, and thus, the availability of
acetyl-CoA is required. Some studies suggested that to maintain this
accelerated citrate oxidation, alterations in fatty acid metabolism are
needed to provide both ATP and acetyl-CoA [27,33,34] (Figure 1).
Beyond the Krebs cycle and glycolysis, glucose also can be degraded
by the pentose phosphate pathway. This metabolic pathway provides
NADPH and ribose-5-phosphate (important for the synthesis of
nucleic acids and nucleotides), thus promoting anabolic reactions and
redox homeostasis. In a recent study, Tsouko et al. (2014)
demonstrated that androgen receptor (AR) signaling augmented the
levels of glucose-6-phosphate dehydrogenase (G6PD) (key enzyme
for pentose phosphate pathway), NADPH, and ribose synthesis in
hormone-sensitive PCa cells and castrate-resistant PCa (CRPC) cells.
After inhibition of mammalian target of rapamycin with rapamycin,
the upregulation of G6PD is abolished. Hence, these studies revealed
a relationship between the upregulation of G6PD via AR and
mammalian target of rapamycin. These results suggested the
importance of pentose phosphate pathway for PCa growth [35].
Cell proliferation and intercellular signaling are dependent on
increased lipid biosynthesis. Acetyl-CoA also plays an important role
in this metabolic alteration because it is a precursor for lipogenesis and
cholesterogenesis and can be produced by transformation of citrate in
the cytosol [1]. Sterol regulatory element-binding protein–1, an
essential transcription factor for lipogenesis, is also implicated in AR
transcriptional regulation. Beyond increased lipogenesis, sterol regula-
tory element-binding protein–1 also increased reactive oxygen species
production and the expression of NADPH oxidase, which leads to
proliferation, migration, and invasion of PCa cells [36–38]. In PCa
cells, the levels of choline and creatine are increased because there is an
augmentation of membrane synthesis for cell proliferation [16].
Glutamine also has an important role in the maintenance of
lipogenesis, as well as to provide intermediates for the Krebs cycle
through glutaminolysis (where glutamine is transformed into glutamate
by glutaminase and then glutamate is transformed into
Figure 1. Schematic illustration of the most significantly altered metabolic pathways in PCa cells. Dashed lines = downregulated
pathway; continuous line = upregulated pathway. Metabolites overexpressed in PCa cells are shown in bold. TCA, tricarboxylic acid
(cycle); AAs, amino acids; DNA, deoxyribonucleic acid; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; G6P,
glucose-6-phosphate; 6P, 6-phosphate; 3PG, 3-phosphoglycerate; CoA, coenzyme A.
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glutaminase are both overexpressed in PCa cells was proof of the
importance of this mechanism in PCa [38–40]. The α-ketoglutarate
derivate from glutamine can contribute to the formation of citrate when
incorporated into the Krebs cycle (oxidation pathway); however,
α-ketoglutarate can also be transformed into citrate by the reversal of the
tricarboxylic acid cycle through reductive carboxylation. This alteration
of oxidation to reductive carboxylation is promoted by hypoxia and
leads to lipid synthesis and tumor growth [41]. The tumor-stromal
interactions also have an important role in PCa development. The
myofibroblastic microenvironment, formed from the interaction of
cancer cells with “cancer-associated fibroblasts”, is important for the
reverse Warburg effect. Cancer-associated fibroblasts in the myofibro-
blastic microenvironment undergo the Warburg effect, induced by
epithelial cancer cells, and secrete lactate and pyruvate. The lactate and
pyruvate are taken up by the PCa cells and used for the Krebs cycle,
anabolic metabolism, and cell proliferation [38,42,43].
Metabolomics Studies in PCaModel Systems and Biological Fluids
The most common models and biological fluids used to perform
metabolomics studies are tissue and cultured cell lines and human
urine, serum/plasma, prostatic fluid/seminal fluid, respectively.The use of urine as a sample for metabolomics studies has many
advantages compared with serum: urine is easier to obtain and handle,
needs less sample preparation, and has higher amounts of metabolites
and a lower protein content [12,44,45]. Blood plasma/serum has
some advantages compared with urine, as the diurnal variation and
the intra- and intervariability are lower. However, serum and plasma
are more complex matrices than urine, having a higher concentration
of proteins, and sample collection is more invasive [5].
Seminal fluids, obtained by ejaculation, come from the seminal
vesicles, prostate, and epididymis. Prostatic fluid is collected after
prostate massage, and the composition of this biofluid is simpler than
seminal fluid [46,47]. The use of seminal/prostatic fluids has some
advantages compared with the use of other biofluids, as these samples
are richer in prostatic metabolites because the metabolites do not
need to cross blood-tissue barriers once they are naturally secreted
into the seminal/prostatic fluid. Thus, seminal/prostatic fluids are
less affected by confounding factors. However, these biofluids may
be difficult to collect in men with erectile dysfunction, and a portion
of men may have personal or ethical problems with giving these types
of samples [48].
The collection of tissue samples is more invasive than the collection
of other matrices; however, the use of matched malignant and normal
Table 1. Metabolomic Studies Performed in Urines from PCa Patients
PCa Subject
Group
Control Group Analytical
Platform
Statistical
Methods
Total Metabolites
Found/Discrimina-
t i v e Me t abo l i t e s
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways Dysregulated Ref.
n= 13 n= 24 GS-MS Binary strings,
Similarity
coefficients
91/21 Butyrolactone, methyl vinyl ketone,
methylamine, N-ethylformamide,
acetonitrile dimethylamino, pyridine,
N-methyl-formamide, acetaldehyde,
acetamide, 1-methyl-piperidine,
1-piperidineacetonitrile, dimethylamine,
pyrrole, methacrolein, N-N-dimethylamine,
3-methyl-pyridine, 2-methyl-1H-pyrrole,
2-octanone, 1-ethyl-1H-pyrrole,
2-n-butylacrolein and methyl propyl disulfide
NS [65]
n= 59 n= 51 LC-MS
GS-MS
Wilcoxon P test,
hierarchical
clustering,
nonparametric
tests
583/34 Sarcosine (+) Alterations in glycine synthesis
and degradation
[53]
n= 106 n= 57
(33 patients with
no evidence of
malignancy plus 24 HC)
GC-MS Nonparametric
statistical tests
and ROC
NS/0 No relevant differences in sarcosine levels
between patients with and without PCa
[61]
n= 3 n= 5 LC-MS NS NS/5 1.Sarcosine
2.Proline
3.Kynurenine (+)
4.Uracil (+)
5.Glycerol 3-phosphate (+)
1. Alterations in glycine synthesis
and degradation
Sarcosine is an intermediate
compound in the metabolism of choline.
2. Alteration in amino acids metabolism
3. Alteration in kynurenine pathway
4. Alteration in pyrimidine metabolism
5. Alteration in energetic metabolism
[55]
n= 25 PCa patients
developing
biochemical
recurrence
n= 29 PCa patients
who remained
recurrence-free
GC-MS ROC 8/2 Sarcosine (+)
Cysteine (+)
(in the group developing
biochemical recurrence)
Alterations in glycine synthesis
and degradation
[56]
n= 33 n= 23
(13 HC plus 10
patients with BPH)
GC-MS Nonparametric
statistical tests
and ROC
NS/1 Sarcosine (+) Alterations in glycine synthesis
and degradation
[57]
n= 86 n= 45 LC-MS ROC NS/1 Diagnostic value of sarcosine was modest;
relationship with clinicopathologic
parameters was not found
Alterations in glycine synthesis
and degradation
[58]
n= 20 n= 28 (8 patients with
BPH plus 20 HC)
GC-MS PCA
ROC
81/5 Dihydroxybutanoic acid (+), xylonic acid (+),
pyrimidine (−), ribofuranoside(−),
and xylopyranose(−)
Alterations in carbohydrate and
energy metabolism
[60]
n= 211 n= 134 GC-MS ROC NS/1 Sarcosine (+) Alterations in glycine synthesis
and degradation
Sarcosine is an intermediate
compound in the metabolism of choline.
[59]
n= 32 n= 32 LC-MS
GC-MS
PCA
PLS-DA
1132/15 1. Glycine (−), serine(−), threonine (−),
alanine (−)
2. Glutamine (−), citrate (−), aconitate (−),
succinate (−)
3. Sucrose (−), sorbose (−), arabinose (−),
arabitol (−), inositol (−), galactaric acid (−)
4.Carnitines (−)
1. Alteration in amino acids metabolism
2. Disturbance in energy metabolism
3. Dysregulation in carbohydrates
degradation
4. Alteration in long-chain fatty
acids metabolism
[63]
n= 59 n= 43 GC-MS RF
LDA
196/4 1. 2,6-dimethyl-7-octen-2-ol (−),
3-octanone (−), 2-octanone (−)
2. Pentanal (+)
1. Increase of utilization of these
metabolites for increased
energy consumption
2. Inflammatory conditions via
the excessive production of
reactive oxygen species, known
to induce lipid peroxidation
[64]
BPH, benign prostatic hypertrophy; GS-MS, Gas chromatography–mass spectrometry; HC, healthy controls; LDA, linear discriminant analysis; LC-MS, Liquid chromatography–mass spectrometry; NS,
not specified; PCA, Principal component analysis; PLS-DA,Partial least squares discriminant analysis RF, random forest; ROC, receiver-operator characteristic.
(+): levels increased in PCa; (−): levels decreased in PCa.
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variability in metabolomics studies [49].
In vitro models are increasingly used because of interindividual
variability, and difficulties enrolling patients in these models are
nonexistent. In addition, cell lines have a perfectly defined cell state
which allows the analysis of a targeted metabolic status [2,50,51].However, they do not efficiently simulate the complex cell-cell and
cell-matrix interactions occurring within an organism [2,52].
There are two different metabolomics approaches to discover
biomarkers for cancer: the top-down approach and the bottom-up
approach. Both approaches have advantages and disadvantages. The
top-down approach has the advantage of starting the metabolome
Table 2. Metabolic Studies in Serum/Plasma from PCa patients
PCa Subject
Group
Control Group Analytical
Platform
Statistical
Methods
Total Metabolites
Found/
Discriminative
Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways
Dysregulated
Ref.
n= 962 n= 1061 HC GC-MS Conditional
logistic
regression
NS/5 Palmitic acid (+), stearic acid (−),
myristic acid (+), linolenic acid (+),
eicosapentaenoic
acids (+)
Alteration in lipid metabolism [70]
n= 85 HG
plus n= 120
LG
n= 114 HC F I A - M S / M S
LC-MS/MS
ROC and
logistic
regression
model
112/5 1. Lysophosphatidyl-choline
(C16:0 and C18:0) (−)
2. Serotonin (−)
3. Aspartic acid (+)
4. Ornithine (−)
1. Alteration in lipid
metabolism
2. Alteration in growth
inhibition and induction
of apoptosis
3. Alteration in protein
biosynthesis
4. Ornithine decarboxylase
overexpression
[75]
n= 561 n= 1034 HC GC-MS
LC-MS
Wilcoxon
signed rank
tests and
χ2 tests
7/3 Choline (+), vitamin B2 (+),
methylmalonic acid (−)
Alteration in membrane
phospholipidic metabolism
[71]
n= 134 n= 666 HC LC-MS ROC 19/7 Glutamine (−), alanine (+),
valine (−), isoleucine (+),
tryptophan (−), ornithine (+),
lysine (+)
Alteration in free amino
acid metabolism
[73]
n= 28
Serum from
patients developing
biochemical
recurrence
n= 30
Serum from
patients with
recurrence free
5 years after
prostatectomy
LC-MS
GC-MS
ROC 9/3 Cystathionine (+),
homocysteine (+), cysteine (+)
Alteration in methionine
metabolism
[56]
n= 36
Fasting plasma
from PCa patients
3 months after
the therapy
initiation
n= 36
Fasting plasma
from PCa before
starting androgen
deprivation therapy
LC-MS
GC-MS
t tests 504/56 1. DHEAS (−), epiandrosterone
sulfate (−), androsterone sulfate (−),
cortisol (−), 4-androsten-3β (−),
17β-diol disulfates 1 & 2 (−),
5α-androstan-3β (−) 17β-diol
disulfate (−), pregnen-diol disulfate (−),
pregn steroid monosulfate (−) and
andro steroid monosulfates 1 & 2 (−).
2. Cholate (+), glycocholate (+),
taurocholate (+), chenodeoxycholate (+),
taurochenodeoxycholate (+),
ursodeoxycholate (+),
hyodeoxycholate (+), deoxycholate (+),
taurodeoxycholate glycodeoxycholate (+),
glycochenodeoxycholate (+),
7-ketodeoxycholate (+)
glycochenodeoxycholate (+),
glycolithocholate sulfate (+),
taurolithocholate 3-sulfate (+),
glycocholenate sulfate (−), and
taurocholenate sulfate (−)
3. Carnitines (−), ketone bodies (−),
dicarboxylic acids
4. 2-hydroxybutyrate (−) and
branched-chain keto-acid
dehydrogenase complex products (−)
1. Steroids metabolism
2. Bile acids and intermediates
of bile acid metabolism
3. Lipid oxidation
4. Markers of insulin resistance
[78]
n= 290 n= 312 Fluorometric assay ROC 1/1 Sarcosine (+) Alterations in glycine synthesis
and degradation
[66]
n= 105 n= 36 ESI-MS/MS PCA and
HCA
390/35 Phosphatidylethano-lamine (+),
ether-linked phosphatidylethanola
mine (+), ether-linked
phosphatidylcholine (+)
Alteration in lipid metabolism [72]
n= 1122
(813 serum
from patients with
nonaggressive PCa
plus 309 serum
from patients with
aggressive PCa
(Gleason score 8))
n= 1112 LC-MS ROC NS/1 Sarcosine (+) Alterations in glycine synthesis
and degradation
[67]
n= 25 n= 100 HC Immunoassay NS 4/1 Insulin (+) Alteration in energetic
metabolism
[76]
n= 64 n= 50 HC LC-MS PCA 480/49 Azelaic acid, uric acid, tryptophan, lysoPC Alteration in fatty acids [69]
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TABLE 2 (continued)
PCa Subject
Group
Control Group Analytical
Platform
Statistical
Methods
Total Metabolites
Found/
Discriminative
Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways
Dysregulated
Ref.
PLS (18:0/0:0), 3-oxo-9,11-tridecadienoic acid,
3-hydroxy-tetradecanedioic acid,
6-hydroxy-pentadecanedioic acid,
5-(2-methylpropyl)-2-oxooxolane-3-carboxylic
acid, 5-butyl-2-oxooxolane-3-carboxylic acid,
lysoPE (0:0/18:2), LysoPE (18:2/0:0),
lysoPC (18:2/0:0), cortolone-3-glucuronide,
pregnanetriol glucuronide, androstenedione,
decanoic acid, menthol glucuronide,
citronellol glucuronide,
l-α-amino-1H-pyrrole-1-hexanoic acid,
lysoPC (0:0/18:2), phenylalanyl phenylalanine
3β,16α-dihydroxyandrostenone sulfate,
2-tert-butyl-1,4-benzenediol sulfate, indoxyl
sulfuric acid,10-dihydroxy-12Z,15Z-
octadecadienoic acid,12,13-dihydroxy-9Z,
15Z-octadecadienoic acid, 5,16-dihydroxy-
9Z,12Z-octadecadienoic acid, 27-nor-
5β-cholestane-3α,7α,12α,24,25-pentol glucuronide,
hexadecanedioic acid phenylacetylglutamine,
heptadecanoic acid, n-[(3α,5β,7β)-7-hydroxy-24-oxo-
3-(sulfooxy)cholan-24-yl]-glycine, n-[(3α,5β,7α)-
3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-glycine,
glycochenodeoxycholate-3-sulfate, 5-isopropyl-2-
methylphenol, sulfate, 5-carboxy-α-chromanol glucuronide,
indole-3-carboxaldehyde, androsterone sulfate,
5α-dihydrotestosterone sulfate and etiocholanolone sulfate
metabolism, amino acids
metabolism, lysophospholipids
metabolism, and bile acids
metabolism and alteration in
steroid hormone biosynthesis
pathway
n= 70
40 LG PCa plus
30 HG PCa
n= 32 HC 1H-NMR PCA,
OPLS-DA
and ROC
NS/4 1.Alanine (+), pyruvate(+)
2.Sarcosine (+) glycine (−)
1. Alteration in energetic
metabolism and lipogenesis
2. Alterations in glycine
synthesis and degradation
[68]
n= 29 n= 21 BPH NMR
LC-MS
GC-MS
PCA and
ROC
348/53 1. Acylcarnitines
2. Choline (glycerol-phospholipids)
3. Arginine
1. Alteration in fatty acids
metabolism
2. Alteration in membrane
phospholipidic metabolism
3. Alteration in amino acids
metabolism
[74]
BPH, Benign prostatic hypertrophy; DHEAS, dehydroepiandrosterone sulfate; HC, Healthy Controls; HCA, hierarchical clustering analysis; GS-MS, Gas chromatography–mass spectrometry; HG, high
grade; LC-MS, Liquid chromatography–mass spectrometry; LG, low grade; NS, Not specified; OPLS-DA, orthogonal partial least squares discriminant analysis; PCA, principal component analysis; PLS,
Partial least squares; ROC, Receiver-Operator Characteristic.
(+): levels increased in PCa; (−): levels decreased in PCa.
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clinical practice. However, urine and plasma are complex biological
matrices and have metabolites from different origins, and the
metabolites may be more diluted. The advantage of the bottom-up
approach (starts with the metabolic analyses of cell lines) is that cultured
cell lines are a simpler biological system with less interference factors. In
fact, studies with immortalized cultured cells are important to eliminate
confounding factors, such as the age of patients, smoking habits, diet,
and other diseases that influence the intervariability in plasma and urine.
Nevertheless, the findings in cultured cell lines may not be directly
extrapolated to the real disease as it is practically impossible to simulate
complex cell–cell and cell–matrix interactions in cell cultures of PCa.
Both approaches used together can be useful tools to obtain metabolic
information that can discriminate the metabolic pathways in PCa cells.
Studies with Human Fluids and Model Systems
Urine Studies. Table 1 summarizes the major metabolites and
metabolic pathways that have been found to be dysregulated in
metabolomics studies performed on urine samples from PCa patients.
One of the most relevant metabolomics studies was performed by
Seekumar et al. (2009), where sarcosine (N-methylglycine)was discoveredas possible biomarker in urine for PCa. Sarcosine, an intermediate
product in the synthesis and degradation of glycine, was found to be
highly elevated during PCa progression tometastasis andwas not detected
or was presented at very low concentrations in the urine of healthy
individuals [53]. Carcinogenesis alters the biosynthesis of sarcosine,
although the importance of sarcosine in carcinogenesis remains unknown.
It is known that glycineN-methyltransferase (GNMT) has a significant role
in the metabolism of PCa tissues. This enzyme catalyzes the conversion of
glycine to sarcosine and also participates both in the metabolism of
methionine and in gluconeogenesis [54]. Similar results were achieved in
other studies performed with different analytical platforms using urine as
the matrix (Table 1) [55–59]. However, other studies concluded that
urinary sarcosine levels were not significantly different between PCa
patients and healthy controls (Table 1) [60,61]. According to Issaq and
Veenstra (2011), several causes for such divergences can be associated to
different study design andmethods, which can have diverse specificities and
sensitivities, and also to interindividual differences [62].
Others common metabolic alterations detected in urine from PCa
patients are alterations in amino acids, organic acids, sphingolipids,
fatty acids, and carbohydrates. Dysregulation of carbohydrate
degradation occurs because carbohydrates can be used by cancer
Table 3. Metabolomic Studies in Prostatic and Seminal Fluid from PCa Patients
PCa Subject Group Control Group Analytical
Platform
Statistical Methods Total Metabolites
Found/Discriminative
Metabolites Found
Discriminatory
Metabolites/Biomarkers
Metabolic Pathways Dysregulated Ref.
n= 13 (prostatic fluid) n= 28 chronic prostatitis,
n= 28 adenoma n= 22 HC
Fluorescence Student’s t test and
Kolmogorov-
Smirnov test
1/1 Zinc (−) Lose capability to accumulated zinc [79]
n= 4 (prostatic fluid) n= 10 BPH
n= 12
NMR Multiple regression NS/3 1. Citrate (−)
2. Spermine (−) and
myo-inositol (−)
1. Alteration in energetic metabolism
2. Alteration in polyamines synthesis
[80]
n= 3 (seminal fluid) n= 3
n= 1 BPH
NMR NS NS/1 Citrate (−) Alteration in energetic metabolism [46]
n= 21 (seminal fluid)
n= 7
(prostatic fluid)
n= 16 (seminal fluid)
n= 17 (prostatic fluid)
NMR ROC NS/1 Citrate (−) Alteration in energetic metabolism [81]
n= 52
(prostatic fluid)
n= 26 NMR LR and ROC 9/3 1. Citrate(−)
2. Myo-inositol (−)
and spermine (−)
1. Alteration in energetic metabolism
2. Alteration in polyamines synthesis
[82]
BPH, Benign prostatic hypertrophy; LR, logistic regression; NMR, Nuclear magnetic resonance; NS, Not specified; ROC, Receiver-operator characteristic.
(+): levels increased in PCa; (−): levels decreased in PCa.
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detected; carnitines and their derivatives are important for conserva-
tion of regular mitochondrial function as well as the transport of
activated long-chain fatty acids from the cytoplasm to the
mitochondrial compartment. The results also suggested disturbances
in energy metabolism, including the Krebs cycle, which were expected
given the Warburg effect and the alteration of the activity of
m-aconitase, as previously explained (Table 1) [60,63].
Potentiality of urinary volatile organic compounds to discriminate
between PCa samples and controls was also evaluated in several
different studies. In these studies, volatile organic compounds were
able to differentiate urine from PCa patients and from control
individuals (Table 1) [64,65].
Plasma and Serum Studies. A summary of metabolomics studies
performed on serum and plasma samples can be found in Table 2.
Studies evaluating sarcosine as a biomarker for PCa were performed
in serum samples using different analytical platforms [fluorometric
assay, liquid chromatography–mass spectrometry (LC-MS), and
1H-nuclear magnetic resonance (NMR)]. The results showed that
PCa samples had elevated levels of sarcosine and could distinguish
low-grade from high-grade PCa, suggesting plasmatic level of
sarcosine as a good biomarker for PCa (Table 2) [66–68].
Beyond the alteration in sarcosine levels, metabolomics studies of
serum/plasma from PCa patients also revealed alterations in fatty acids,
amino acids, lysophospholipids, bile acids, and metabolites related to the
steroid hormone biosynthesis pathway. The alteration in fatty acids is
related to changes in lipid β-oxidation necessary to provide energy for
abnormal cell proliferation (Table 2) [69,68,70–75]. Alterations in
energetic metabolism are also common [68,76] (Table 2), and increased
levels of glucose in serum samples at the time of PCa diagnosis were
associated with an increased risk of recurrences after therapy with radical
prostatectomy or radiation therapy [77].
Serum and plasma metabolomics studies can also be used to assess
alterations in the metabolic profile caused by medical treatment. The
metabolic profile of fasting plasma from PCa patients before starting
androgen deprivation therapy and 3 months after the therapy
initiation was analyzed [78]. As expected, steroid levels decreased
during androgen deprivation therapy, whereas the levels of most bile
acids and their metabolites increased with therapy. Bile acids have an
important role in the control of serum lipids, glycemic regulation, and
energy homeostasis. Lower levels of metabolites related to lipidmetabolism after 3 months of treatment were also observed. Carnitines,
ketones, dicarboxylic acids, and the levels of 2-hydroxybutyrate and
branched-chain keto-acid dehydrogenase complex products (bio-
markers of insulin resistance) were also present in lower levels after
the therapy, indicating a reduction in the catabolic state [78].
Prostatic Fluid and Seminal Fluid Studies. Table 3 presents a
summary of metabolomics studies performed in prostatic fluid and
seminal fluid from PCa patients.
Prostatic and seminal fluids are other biofluids that may be used to
perform PCa metabolomics studies to discover alterations in cancer
cell metabolism and noninvasive biomarkers for PCa detection.
As explained previously, normal prostate cells have the ability to
accumulate zinc and consequently accumulate citrate. However, PCa
cells lose this ability. Several metabolomics studies support this
theory. The analysis of prostatic and seminal fluid using different
analytical platforms (fluorescence technique and NMR) revealed
reduced levels of zinc and citrate in PCa groups when compared with
the controls (Table 3) [46,79–82]. Kline et al. (2006) also concluded
that citrate level tests outperform the PSA test in PCa detection.
Additionally, the analysis of citrate in semen has the same efficacy as
the analysis of citrate in prostatic secretion for detecting PCa [81].
Another important function of normal prostate cells is the synthesis
of polyamines, such as spermine and myo-inositol. The analysis of
prostatic and seminal fluid from PCa patients showed significantly
decreased levels of spermine and myo-inositol (Table 3) [80,82]. Serkova
et al. (2008) also demonstrated that the reduction in citrate, spermine,
and myo-inositol levels is independent of the patient’s age [82].
Ex Vivo Tissue Studies. Table 4 presents a summary of
metabolomics studies performed in PCa tissues.
The value of sarcosine as a PCa biomarker was also evaluated in
prostate tissue samples using different analytical platforms. The levels of
sarcosine were increased in PCa samples (Table 4) [15,53,59,83]. Results
also revealed that sarcosine levels were significantly elevated in metastatic
PCa and clinically localized PCa tissue samples, whereas in benign
samples, sarcosine was not detected. These results indicate that sarcosine
may be a good biomarker for monitoring disease progression and
aggressiveness [53].
Other metabolites, namely citrate, lactate, and alanine, were
frequently altered in PCa tissue samples. These results suggest
alterations in citrate synthesis (Krebs cycle) and in energetic
metabolism. As previously explained, the PCa cells switch from
Table 4. Metabolomic Studies in Prostate Cancer Tissue
PCa Subject Group Control Group Analytical
Platform
Statistical Methods Total Metabolites
Found/Discrimi-
native Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways Dysregulated Ref.
n= 21 n= 66
Benign
prostate tissue
MRS LDA NS/6 1. Citrate (−)
2. Taurine (+), glutamate (+)
1. Reduced citrate synthesis
(Krebs cycle)
2. Alteration in energy metabolism
[85]
n= 10
Malignant
human
prostate tissue
n= 10
BPH
1H-NMR Nonparametric test
of Kruskal-Wallis
NS/3 1. Citrate (−)
2. Choline (+)
3. Myo-inositol (+)
1. Reduced citrate synthesis
(Krebs cycle)
2. Increased membrane turnover
3. Altered membrane metabolism
[86]
n= 15
Adenocarcinoma
n= 1
HC
1H-NMR Linear regression analysis NS/2 1. Citrate (−)
2. Spermine (−)
1. Reduced citrate synthesis
2. Reduced spermine synthesis
(amino acid synthesis)
[87]
n= 27
Adenocarcinoma
n= 44
BPH
MRS NS 22/3 1. Citrate (−)
2. Choline (+)
3. Lipid/lysine ratio (+)
1. Reduced citrate synthesis
2. Increased membrane turnover
3. Increased cellular proliferation
[88]
n= 20 n= 33
Benign tissue
1H-NMR Nonparametric
Spearman correlation
coefficients
NS/8 1. Choline (+), phosphocholine (+),
glycerophospho-choline (+)
2. Taurine (+)
3. Myo-inositol (+), scyllo-inositol (+)
4. Citrate (−), polyamines (−)
1. Alteration in phospholipid
membrane synthesis and hydrolysis
2. Alteration in energy metabolism
3. Altered membrane metabolism
4. Reduced citrate and polyamines synthesis
[89]
n= 15 n= 32
Benign
prostatic tissue
1H-NMR Z statistics NS/5 Phosphocholine (+), glycerol-
phosphocholine (+),
phosphor-ethanolamine (+),
glycerophospho-ethanolamine (+),
ethanolamine (−)
Alterations on phospholipid
membrane assembly and catabolism
[92]
n= 16 n= 82
Benign
prostate biopsies
1H-NMR NS NS/2 1. Lactate (+)
2. Alanine (+)
1. “Warburg effect”
2. Intensification in glycolytic
flux and increased protein
synthesis in cancer cells
[90]
n= 18 n= 30 1H-NMR LR NS/7 tCho/Cit (+), Cho/Cr (+),
GPC + PC)/Cr (+), Lac/Al (+) Cit/Cr (−)
Alterations in citrate synthesis
(Krebs cycle), in membrane
turnover, and in energetic
metabolism
[84]
n= 12 Localized
PCa n= 14
metastatic PCa
n= 16 Benign
tissue
adjacent to PCa
LC-MS
GC-MS
Wilcoxon P test,
hierarchical clustering,
nonparametric tests
626/60 1. Sarcosine (+)
2. Uracil (+)
3.Kynurenine (+)
4. Glycerol-3-phosphate (+),
5. Leucine (+), proline (+)
1. Alterations in glycine
synthesis and degradation
Sarcosine is an intermediate
compound in the metabolism
of choline.
2. Alterartion in pyrimidine
metabolism
3.Alteration in Kynurenine pathway
4. Alteration in energetic metabolism
5. Alteration in amino acids metabolism
[53]
n= 27 n= 54 NMR NS NS/NS Omega-6 PUFA (+) Alteration in lipid metabolism [95]
n= 16
patients with
chemical failure
n= 32
Patients without
recurrence after
prostatectomy
1H-NMR PCA NS/6 1. Spermine
2. Myo-inositol, phosphoryl, scyllo-inositol
3. Choline
4. Glutamate, glutamine
1. Reduced spermine synthesis
(amino acid synthesis)
2. Altered membrane metabolism
3. Alteration in phospholipid
membrane synthesis and hydrolysis
4.Alteration in energy metabolism
[93]
n= 41 n= 108
Benign adjacent
prostate tissue
1H-NMR Binary logistic regression
and multivariate
linear regression
13/6 1. Choline compounds (+)
2. Myo-inositol (−), scyllo-inosito (+)
1. Alteration in phospholipid
membrane synthesis and hydrolysis
2. Altered membrane metabolism
[94]
n= 92 n= 92 GC-MS Nonparametric statistical
tests and ROC
NS/1 Sarcosine (+)
(sarcosine levels were not related with
tumor stage, grade or
biochemical recurrence)
Alterations in glycine synthesis
and degradation. Sarcosine is an
intermediate compound in the
metabolism of choline.
[83]
n= 331 n= 178 GC-MS
LC-MS
ROC 469/200 1. Sarcosine (+)
2. Kynurenine (+)
3. Proline (+)
4. Uracil (+)
5.Glycerol-3-phosphate (+), threonine (+)
citrate (−) ADP-ribose (−)
15-hydroxyeicosatetraenoic acid(−)
6.Polyanines (−)
1. Alterations in glycine
synthesis and degradation
Sarcosine is an intermediate
compound in the metabolism of choline.
2. Alteration in kynurenine pathway
3.Alteration in amino acids metabolism
4.Alterartion in pyrimidine metabolism
5.Alteration in energetic metabolism
6.Reduced polyamines synthesis
[15]
n= 11
Localized PCa
plus n= 10
metastatic PCa
n= 11
Benign adjacent
prostate samples
GC-MS ROC NS/1 Sarcosine (+) (progressive elevation from
benign tissue to localized tumors and
metastatic disease)
Alterations in glycine synthesis
and degradation
Sarcosine is an intermediate
compound in the metabolism of choline.
[59]
(continued on next page)
Translational Oncology Vol. 9, No. 4, 2016 Biomarker Discovery in Human Prostate Cancer Lima et al. 369
TABLE 4 (continued)
PCa Subject Group Control Group Analytical
Platform
Statistical Methods Total Metabolites
Found/Discrimi-
native Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways Dysregulated Ref.
n= 95 n= 95
Normal adjacent
prostate tissue
GC-MS
LC-MS
ROC,
Univariate Cox regression,
Kaplan-Meier analyses,
and multivariate Cox
regression analyses
820/9 1. Gluconic acid (−), maltotriose (−)
2. Aminoadipic acid (+)
3. Cerebronic acid (+),
glycerophosphoethanol-amine (+),
2-hydroxybehenic acid (+), tricosanoic acid (+)
4. Isopentenyl pyrophosphate (+)
5. 7-methylguanine (+)
1. Alteration in carbohydrate metabolism
2. Increased fatty acid synthesis
3. Alteration in lipid metabolism
4. Intermediate in the steroid
synthesis pathway, indicates
an increase of cholesterol levels
5. DNA damage
[49]
n= 30 LG PCa plus
n= 81 HG PCa
n= 47
Normal
adjacent tissue
MRS PCA, PLS and PLS-DA 23/2 1. Citrate (−)
2. Spermine (−)
1. Reduced citrate synthesis
2. Reduced spermine synthesis
[91]
BPH, Benign prostatic hypertrophy; Cho/Cr, choline/creatinine; Cit/Cr, citrate/creatinine; GS-MS, Gas chromatography–mass spectrometry; (GPC + PC)/Cr, (glycerol-phosphocholine +
phosphoryl-choline)/creatinine; HC, Healthy Controls; HG, High grade; Lac/Al, lactate/alanine; LC-MS, Liquid chromatography–mass spectrometry; LDA, Linear discriminant analysis; LG, Low
grade; LR, Linear regressionMRS, magnetic resonance spectroscopy; NMR, Nuclear magnetic resonance; NS, Not specified; PCA, Principal component analysis; PLS, partial least squares; PLS-DA, partial
least squares discriminant analysis; tCho/Cit, total choline/citrate.
(+): levels increased in PCa; (−): levels decreased in PCa.
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PCa cells also undergo the Warburg effect, all of which explain these
alterations (Table 4) [15,84–91].
It is also well established that cancer cells have elevated
proliferation rates, and this is reflected in alterations in membrane
metabolism. Several metabolomics studies performed in PCa tissue
revealed an increase of choline levels in PCa samples, which indicates
alterations in phospholipid membrane synthesis and hydrolysis
(Table 4) [84,86,88,89,92–94]. Because this elevated proliferation
rate also increases cell energy requirements, PCa samples also have
alterations in lipid metabolism (as lipids may be used by the cells to
produce energy) (Table 4) [49,95].
Beyond the study of the metabolic pathways involved in cancer
development, it is also important to assess which metabolic pathways
are involved in the growth of bone metastases. The results obtained
from a study [78] revealed a significant increase in cholesterol levels in
bone metastases tissues from PCa patients. The metabolic profile
from PCa bone metastases indicates high energy metabolism, which
may be related to highly proliferating cells. This conclusion was based
on the elevated levels of certain metabolites, such as threonine,
glutamate, phenylalanine, citrate, fumarate, glycerol-3-phosphate,
and fatty acids. Another relevant metabolic alteration in PCa bone
metastases tissue was the elevated levels of myo-inositol-1-phosphate,
which may indicate active cell signaling involving inositol-based
compounds as second messengers. Inositol-based molecules are
related to the activation of protein kinase C, and the activation of
this molecule is important for cell proliferation, apoptosis, differen-
tiation, invasion, and angiogenesis. The concentration of sarcosine
was increased in bone metastases from PCa and from other cancers,
which reveals that sarcosine may not be specific to PCa. Metabolites
such as threonine, asparagine, fumarate, and linoleic acid are present
in high levels in samples from bone metastases. The levels of these
metabolites were also increased in samples of primary prostate tissues
from patients with confirmed bone metastases. Linoleic acid, an
essential fatty acid, was associated with PCa progression. Further-
more, linoleic acid may also be associated with the inflammatory
response because linoleic acid is transformed into arachidonic acid.
Arachidonic acid is a precursor for prostaglandins, which have an
important role in inflammation [96].
In Vitro Studies. Table 5 summarizes general information on in
vitro metabolomics studies in PCa-derived cell lines.The biological relevance of sarcosine was evaluated in four
immortalized PCa cell lines, in primary benign prostate epithelial
cells, and in an immortalized benign prostate epithelial cell line.
Sarcosine levels were increased in malignant cell lines when compared
with benign cell lines [53,97]. Furthermore, alterations in the
expression of the enzymes involved in sarcosine metabolism influence
cell proliferation, invasion, and cell death, which suggest the
importance of sarcosine in PCa metabolism (Table 5) [53,59]. In
an effort to understand the role of sarcosine in PCa progression,
Sreekumar et al. (2009) evaluated the role of androgen signaling and
the genes ERG and ETV1 (important mediators of PCa progression).
The results showed that after treatment with androgens, cell lines that
were ERG positive and ETV1 positive had increased GNMT
expression and decreased sarcosine dehydrogenase (SARDH)
expression [53].
In agreement with the results from metabolomics studies
performed in other matrices (urine, plasma/serum, and tissues),
presented here previously, alterations in amino acid metabolism were
also observed in the studies performed in PCa cell lines. PCa cells lines
revealed alterations in the levels of certain amino acids, such as
leucine, valine, or isoleucine (Table 5) [97–99].
The increase of lactate and alanine levels in PCa cell lines is
frequently observed in metabolomics studies. These alterations
suggest changes in cellular energy metabolism (Table 5) [97–100].
As reported for other matrices, metabolomics studies in PCa also
revealed that PCa cells experience alterations in membrane
metabolism with changes, for example, in choline metabolite levels
(Table 5) [98,101]. Androgen signaling has an important role in the
development and progression of PCa. In fact, one current therapy for
metastatic PCa is the use of antiandrogen agents; however, with the
progression of the disease, patients normally develop resistance to this
therapy, and it is currently impossible to predict if the cancer will
progress into a castration-resistant state. The androgen-responsive cell
lines can be characterized by increased levels of spermine, N-acetyl-
spermine, serine, threonine, lysine, homocysteine, asparagine,
alanine, and glutamic acid, as well as decreased levels of
S-adenosylmethionine, with a simultaneous increase in levels of its
breakdown product, homocysteine. These findings indicate that
androgen-responsive cell lines have an elevated methylation activity.
Androgen treatment resulted in further perturbations in amino acid
metabolism and in a shift toward increased methylation.
Table 5. Metabolomic Studies Performed in Human PCa-Derived Cell Lines
Cancer Cell Lines Control Group Analytical
Platform
Statistical
Methods
Total
Metabolites
Found/
Discriminative
Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways
Dysregulated
Ref.
AD prostate carcinoma
LNCaP cell line
Androgen-independent
prostate carcinoma
PC-3 cell line
MRS NS 3/2 Uptake of ethanolamine and
N,N′-dimethylethanolamine (+)
(principally in AD cells in
presence of androgens)
Alteration in membrane
lipid synthesis
[101]
VCaP, DU145,
22RV1, and LNCaP
PrEC and RWPE LC-MS
GC-MS
Wilcoxon
P test,
hierarchical
clustering,
nonparametric
tests
1/1 Sarcosine (+) Alterations in glycine
synthesis and degradation
[53]
Androgen-nonresponsive
PC3 and DU145 cell lines
Androgen-responsive
VCaP (treated with
synthetic androgen)
and LNCaP cell lines
RWPE LC-MS HCA 1553/674 Malignant cell lines
1. Sarcosine (+)
2. Threonine (+), phenylalanine (+),
alanine (+), creatine (+),creatinine (+),
citrulline (+), tryptophan (−),
1-methyl tryptophan (−) and
kyneuric acid (−)
Androgen-responsive cell lines
3. Serine (+), threonine (+), lysine (+),
homocysteine (+), asparagine (+),
alanine (+), glutamic acid (+)
4. S-adenosylmethionine (−), homocysteine (+)
Androgen treatment resulted in further
perturbations in amino acid metabolism
and increased methylation.
1. Alterations in glycine
synthesis and degradation
Sarcosine is an intermediate
compound in the
metabolism of choline.
2. Alteration in amino
acids metabolism
3. Alteration in amino
acids metabolism
4. Elevated methylation
activity
[97]
PC3 and LNCaP treated
with LY294002
(inhibitor of the PI3K
signaling pathway) or
17AAG (inhibitor of
the HSP90 protein chaperone)
PC3 and LNCaP
untreated
MRS PCA NS/24 After both treatments: lactate (−),
alanine (−), fumarate (−)
LY294002 treatment: phosphocholine (−),
glutathione (−), glutamine (+), valine (+),
leucine (+), isoleucine (+)
17AAG treatment: phosphocholine (+),
citrate (+), glutamine (−), valine (+),
leucine (+), isoleucine (+), myo-inositol (+),
taurine (+)
PI3K and HSP90 inhibition [102]
Low-invasiveness
WPE1-NB14 and
high-invasiveness
WPE1-NB11 cell lines
RWPE-1 1H-NMR PLS-DA NS/10 1. Leucine (−), valine (−), isoleucine (−),
glutamine (−), glutamate (−),
β-hydroxyisovalerate (−)
2. Glycine (−)
3. Lactate, alanine
4. Phosphocholine (+)
1. Increased protein
synthesis and amino
acid catabolism
2. Alterations in methylation
and synthesis and
degradation of sarcosine
3. Alteration in energetic
metabolism;
4. Alteration in choline
metabolism
[98]
Androgen-nonresponsive
PC3 and androgen-
responsive LNCaP cell lines
PNT1A 1H-NMR Two-way
analysis of
variance
followed by
Bonferroni
posttest
NS/3 Glucose consumption (+)
PC3 cells:
Lactate (+)
Alanine (+)
Lactate/alanine ratio (+)
Increased levels of oxidative
stress in PC3 cells.
Androgen-responsive and
-nonresponsive PCa cells
showed different glycolytic
metabolism profiles.
[100]
DU145, PC3, and LNCaP
(knockdown of GNMT,
SARDH, or PIPOX and
overexpression of GNMT,
SARDH, or PIPOX
(convert sarcosine
back to glycine)
RWPE GC-MS ROC NS/1 Overexpression of GNMT: sarcosine (+)
(increase in invasion).
Knockdown of GNMT: sarcosine (−)
(reduction in cell proliferation, invasion,
and greater percentage of cell death)
Overexpression of SARDH or PIPOX:
sarcosine (−) (reduced invasion)
Knockdown of SARDH: sarcosine (+)
(increase proliferation and invasion)
Knockdown of PIPOX: sarcosine (+)
(increased invasion)
Alteration in glycine
synthesis and degradation
[59]
CRPC cell C4-2, 22Rv1
and LNCaP-abl
Androgen receptor
positive LNCaP
and MDA-PCa-2a
and
MDA-PCa-2b
LC-MS HCA 150/38 CRPC cells:
1. Sugars and intermediates associated
with energy metabolism and signaling (+)
AD cells
2. Carnitines, amino acids, and their
methylated derivatives (+)
1. Alteration in energy
metabolism and signaling
2. Alteration in amino
acid metabolism
[99]
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TABLE 5 (continued)
Cancer Cell Lines Control Group Analytical
Platform
Statistical
Methods
Total
Metabolites
Found/
Discriminative
Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways
Dysregulated
Ref.
Highly metastatic
LNCaP-LN3 treated
with DCA and poorly
metastatic LNCaP
treated with DCA
LNCaP-LN3 and
LNCaP untreated
NMR Nonparametric
test
NS/3 LNCaP-LN3 treated with DCA: Lac/Cr (−),
Lac/Cho (−), Lac/Al (−), and
Lac/(Cho + Cr + Al) (−)
LNCaP (poorly metastatic) treated with DCA:
no change in lactate/metabolite ratios
Reversion of Warburg
effect (LNCaP-LN3 cells
respond better to DCA)
[103]
AD, Androgen dependent; CRPC, castrate-resistant prostate cancer; DCA, Dichloroacetate; GC-MS, Gas chromatography–mass spectrometry; GNMT, Glycine-N-methyl transferase; HCA, Hierarchical
clustering analysis; Lac/Al, lactate/ alanine; Lac/Cr, lactate/creatine; Lac/Cho, lactate/choline; Lac/(Cho + Cr + Ala), lactate/(choline + creatine + alanine); LC-MS, Liquid chromatography–mass
spectrometry; NMR, Nuclear magnetic resonance; MRS, Magnetic resonance spectroscopy; NS, Not specified; PCA, Principal component analysis; PIPOX, Pipecolic acid oxidase; PLS-DA, Partial least
squares discriminant analysis; ROC, Receiver-operating characteristics analysis; SARD, Sarcosine dehydrogenase.
(+), Levels increased in PCa; (-), Levels decreased in PCa.
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have differences in their glycolytic metabolism profiles.
Androgen-dependent PCa cells and androgen-independent PCa cells
also show differences in membrane lipid synthesis (Table 5) [97,100,101].
Metabolomics studies in cell lines may also be used to evaluate the
alterations that occur after a pharmacological therapy. The treatment
of PCa cells appears to lead to changes in energetic metabolism and
choline metabolism (Table 5) [102]. Dichloroacetate (DCA) is an
inhibitor of pyruvate dehydrogenase kinase, and inhibition of this
enzyme has the potential to reverse the Warburg effect due to the
increased pyruvate uptake into mitochondria. After treatment
with this drug, the highly metastatic cells showed significantly
lower levels of lactate/metabolite ratios [Lac/Cr, Lac/Cho, Lac/Al,
and Lac/(Cho + Cr + Al)], whereas in poorly metastatic cells, no
changes in lactate/metabolite ratios were found after the treatment.
These findings suggest that highly metastatic cells are more dependent
on lactate production (Table 5) [103].
Conclusions and Future Directions
The introduction of PSA testing has radically altered how PCa is
diagnosed andmanaged. However, this test may lead to a false-positive or
false-negative diagnosis. This drawback has given rise to serious efforts
toward the discovery of new biomarkers, preferentially noninvasive,
which have better specificity and sensitivity.
Because metabolic alterations are the last step in the cellular
response to diseases, metabolomics can be successfully used to
discover new biomarkers for cancer. In this regard, several studies
have been conducted to characterize the metabolic profile of PCa.
One of the major obstacles in data interpretation is that the
metabolic profile is influenced by various factors, such as age, diet,
drugs, and chronobiological variations, among others. Additional
problems include sample preparation, the analytical procedures, and
the statistical platforms used. Major differences in these conditions
can compromise the comparison of results among different studies
and consequently compromise the discovery of new biomarkers.
Another intrinsic difficulty with metabolomics studies is the massive
amount of data produced that is difficult statistically to analyze.
Despite these difficulties, metabolomics is a powerful tool for the
discovery of new biomarkers for PCa detection, biomarkers indicative
of cancer prognosis, disease progression, and therapeutic response, as
well as identifying new therapeutic targets.
The metabolomics studies described in this review revealed
different results, but almost all studies in urine, plasma/serum,prostatic fluids, tissues, and cell lines associated PCa with decreased
levels of citrate and polyamines and increased levels of choline, lactate,
and amino acids.
Further studies are still needed to confirm the results of these
studies and identify an inexpensive, noninvasive, sensible, and specific
biomarker for PCa.
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